Skip to content

Released Feb 23, 2021, after the close

10-K filed Feb 23, 2021, 54 days after period end · 0001232524-21-000016

Q4 2020 · 10-K
Revenue$665.52M+14.4% vs Q4 2019+10.8% vs Q3 2020
Net Income$133.41M+80.3% vs Q4 2019−10.0% vs Q3 2020
EPS Diluted$2.33+80.6% vs Q4 2019−11.7% vs Q3 2020
Gross Profit$611,146,000+12.9%
Operating Incomederived$173,414,000+183.1%
Operating Cash Flowderived$186,271,000+112.2%
Free Cash Flowderived$182,156,000+125.8%
Margins · derived
Gross margin91.8%−1.2 pt vs Q4 2019
Operating margin26.1%+15.5 pt vs Q4 2019
Net margin20.0%+7.3 pt vs Q4 2019

What the release said

The release

Same quarter

MetricQ4 2020Q4 2019Q4 2018Q4 2017
Revenue$665.52M$581.74M$476.46M$436.40M
Net Income$133.41M$73.99M$159.47M$232.21M
EPS Diluted$2.33$1.29$2.64$3.79

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR